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Curcuma longaL. (Zingiberaceae family) and its polyphenolic compound curcuminhave been subjected to a variety of antimicrobial
investigations due to extensive traditional uses and low side effects. Antimicrobial activities for curcumin and rhizome extract of
C. longa against different bacteria, viruses, fungi, and parasites have been reported.The promising results for antimicrobial activity
of curcumin made it a good candidate to enhance the inhibitory effect of existing antimicrobial agents through synergism. Indeed,
different investigations have been done to increase the antimicrobial activity of curcumin, including synthesis of different chemical
derivatives to increase its water solubility as well ass cell up take of curcumin.This review aims to summarize previous antimicrobial
studies of curcumin towards its application in the future studies as a natural antimicrobial agent.
1. Introduction
Curcumin or diferuloylmethane with chemical formula
of (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione) (Figure 1) and other curcuminoids constitute the
main phytochemicals of Curcuma longa L. (Zingiberaceae
family) rhizome with the common name of turmeric [1].
This polyphenolic compound due to a variety of biological
activities has been gained significant attention of researches
all over the world [2–5]. Turmeric, an ancient coloring spice
of Asia, as the main source of curcumin is traditionally used
for many remedies [6]. As shown in Figure 2, curcumin
due to a variety of specific characterizations is in interest
of scientists in recent years. As many other plant materials,
there are differences in the curcumin content for theCurcuma
longa from different geographical regions and it could be due
to hybridization with other Curcuma species which could be
important fact to choose the plant with higher content of
curcumin [4].
Curcuma longa rhizome has been traditionally used as
antimicrobial agent as well as an insect repellant [7]. Sev-
eral studies have reported the broad-spectrum antimicrobial
activity for curcumin including antibacterial, antiviral, anti-
fungal, and antimalarial activities. Because of the extended
antimicrobial activity of curcumin and safety property even
at high doses (12 g/day) assessed by clinical trials in human,
it was used as a structural sample to design the new antimi-
crobial agents with modified and increased antimicrobial
activities through the synthesis of various derivatives related
to curcumin [8, 9]. It was even studied as an antimicrobial
agent suitable for textile materials. Results showed that
curcumin in combination with aloe vera and chitosan could
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Figure 1: Chemical structure of curcumin.
be a potential suppressor for microbial growth in cotton,
wool, and rabbit hair assessed by the exhaustionmethod [10].
Either the continuous or batch dyeing process with curcumin
provided textiles with antimicrobial properties beside the
color. Curcumin finished wool had semidurable antimi-
crobial activity, less durable to light exposure than home
laundering with 45% and 30% inhibition rates against Staphy-
lococcus aureus and Escherichia coli, respectively, after 30
cycles of home laundering [11]. Mixture of curcumin with
other antimicrobial agents is used for the development of
antimicrobial skin gels and emulsions with improved skin
protection and wound dressing properties [12]. Composition
of curcumin with hydrogel silver nanoparticles is used to
increase the function of hydrogel silver nanocomposites as
marked substances for antimicrobial applications and wound
dressing [12]. Curcumin-loadedmyristic acidmicroemulsion
with the 0.86 𝜇g/mL of curcumin suitable for skin consump-
tion inhibited 50% of the S. epidermidis growth as one of
the nosocomial infectious agents. It showed 12-fold stronger
inhibitory effect compared to curcumin activity dissolved in
dimethyl sulfoxide (DMSO) [13].
2. Antibacterial Activity
Bacterial infections are among the important infectious dis-
eases. Hence, over 50 years of extensive researches have been
launched for achieving new antimicrobial medicines isolated
from different sources. Despite progress in development of
antibacterial agents, there are still special needs to find
new antibacterial agents due to development of multidrug
resistant bacteria [14]. The antibacterial study on aqueous
extract of C. longa rhizome demonstrated the MIC (min-
imum inhibitory concentration) value of 4 to 16 g/L and
MBC (minimum bactericidal concentration) value of 16
to 32 g/L against S. epidermis ATCC 12228, Staph. aureus
ATCC 25923, Klebsiella pneumoniae ATCC 10031, and E.
coli ATCC 25922 [15]. The methanol extract of turmeric
revealed MIC values of 16 𝜇g/mL and 128 𝜇g/mL against
Bacillus subtilis and Staph. aureus, respectively [16].The study
of hexane and ethanol turmeric extract and curcuminoids
(from ethyl acetate extract of curcuminoids isolated from
C. longa with 86.5% curcumin value) against 24 pathogenic
bacteria isolated from the chicken and shrimp showed the
highest antimicrobial activity for ethanol extract with the
MIC value of 3.91 to 125 ppt [17]. The hexane and methanol
extracts of C. longa demonstrated antibacterial effect against
13 bacteria, namely, Vibrio harveyi, V. alginolyticus, V. vul-
nificus, V. parahaemolyticus, V. cholerae, Bacillus subtilis, B.
cereus, Aeromonas hydrophila, Streptococcus agalactiae, Staph.
aureus, Staph. intermedius, Staph. epidermidis, and Edward-
siella tarda. However, curcuminoids elicited inhibitory activ-
ities against 8 bacteria of Str. agalactiae, Staph. intermedius,
Staph. epidermidis, Staph. aureus, A. hydrophila, B. subtilis,
B. cereus, and Ed. tarda. Hexane extract and curcuminoids
exhibited the MIC values of 125 to 1000 ppt and 3.91 to
500 ppt, respectively [17]. Indeed, it was shown that the
addition of 0.3% (w/v) of aqueous curcumin extract to the
cheese caused the reduction in bacterial counts of Salmonella
typhimurium, Pseudomonas aeruginosa, and E. coli 0157:H7.
Moreover, it has decreased the Staph. aureus, B. cereus,
and Listeria monocytogenes contamination after 14 days of
cold storage period [18]. Turmeric oil as a byproduct from
curcumin manufacture also was found effective against B.
subtilis, B. coagulans, B. cereus, Staph. aureus, E. coli, and P.
aeruginosa [19]. Curcumin also exhibited inhibitory activity
on methicillin-resistant Staph. aureus strains (MRSA) with
MIC value of 125–250𝜇g/mL [20]. The in vitro investigation
of 3 new compounds of curcumin, namely, indium curcumin,
indium diacetyl curcumin, and diacetyl curcumin, against
Staph. aureus, S. epidermis, E. coli, and P. aeruginosa revealed
that indium curcumin had a better antibacterial effect com-
pared to curcumin itself and it may be a good compound
for further in vivo studies. However, diacetylcurcumin did
not exhibit any antibacterial effect against tested bacteria [21].
These results demonstrated promising antibacterial activity
for different curcumin derivatives as well. The stability and
assembly of FtsZ protofilaments as a crucial factor for bac-
terial cytokinesis are introduced as a possible drug target
for antibacterial agents. Curcumin suppressed the B. subtilis
cytokinesis through induction of filamentation. It also with-
out significantly affecting the segregation and organization
of the nucleoids markedly suppressed the cytokinetic Z-ring
formation in B. subtilis [22]. It was demonstrated that cur-
cumin reduces the bundling of FtsZ protofilaments associated
with the binding ability to FtsZ with a dissociation constant
of 7.3 𝜇M. It showed that curcumin via inhibition of assembly
dynamics of FtsZ in the Z-ring can possibly suppress the
bacterial cell proliferation as one of the probable antibacterial
mechanisms of action [22]. The study on E. coli and B.
subtilis demonstrated that curcumin by the inhibitory effect
against FtsZ polymerization could suppress the FtsZ assembly
leading to disruption of prokaryotic cell division [23].
Also, curcumin showed significant antibacterial activity
with MIC values between 5 and 50 𝜇g/mL against 65 clinical
isolates of Helicobacter pylori [41]. Curcumin also has an
inhibitory effect on NF-𝜅B activation and as a result on the
release of IL-8 and cell scattering which led to a reduction
in inflammation of gastric tissue as the main consequence
for H. pylori in stomach. It inhibits the I𝜅B𝛼 degradation,
the activity of NF-𝜅B DNA-binding and I𝜅B kinase 𝛼 and 𝛽
(IKK 𝛼 and 𝛽) [42]. Indeed, curcumin inhibited the matrix
metalloproteinase-3 andmetalloproteinase-9 activity (MMP-
3 and MMP-9) as inflammatory molecules involved in H.
pylori infection in mice and in cell culture with a dose
dependent manner [43]. Curcumin showed more efficient
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Figure 2: Importance of curcumin in antimicrobial studies.
therapeutic index than conventional triple therapy of H.
pylori on MMP-3 and MMP-9 via reduction of activator
protein-1 and proinflammatory molecule activation in H.
pylori infected gastric tissues [43]. In vivo study of antibac-
terial effect of curcumin on H. pylori compared to OAM
(Omeprazole, Amoxicillin, and Metronidazole) treatment
revealed poor activity for eradication ofH. pylori (5.9% versus
78.9% for OAM treatment). The reduction in inflammatory
cytokine production was not reported from pylori-infected
patients treated with curcumin [44]. The in vivo study
of 1-week nonantibiotic therapy comprised of curcumin,
pantoprazole, N-acetylcysteine, and lactoferrin against H.
pylori infection was not effective for the eradication of H.
pylori. However, the decrease in immunological criteria of
gastric inflammation and dyspeptic symptoms was reported
after 2 months of treatment schedule [45]. Nevertheless, the
curcumin administration to the rats with H. pylori-induced
gastric inflammation revealed a significant reduction in
macromolecular leakage and NF-𝜅B activation [46]. In an in
vivo study of H. pylori-infected C57BL/6 mice administered
with curcumin exhibited immense therapeutic potential and
pronounced eradication effect against H. pylori infection
associated with restoration of gastric damage [41].
2.1. Synergistic Antimicrobial Activity. The outburst of drug
resistant microbial strains necessitates the studies for syn-
ergistic effects of antibiotics in combination with plant’s
derivatives to develop the antimicrobial cocktail with a wider
spectrum of activity and reduction of adverse side effects of
antimicrobial agents. Staph. aureus resistance to the penicillin
group of antibiotics is increasing associated with appearance
of adverse side effects such as hypersensitivity and anaphy-
lactic reactions [47]. The synergistic activity of curcumi-
noids and ampicillin combination demonstrated pronounced
reduction in the MIC of ampicillin against either clinical
strain or Staph. aureus ATCC 25923 strain. Bacteriocin sub-
tilosin isolated fromB. amyloliquefaciens in combinationwith
encapsulated curcumin revealed partial synergism against
wild-type and nisin sensitive strains of L. monocytogenes
Scott A [48]. In another in vivo study using 500 𝜇g/disc
of curcumin against clinical isolate of Staph. aureus the
synergistic activity with antibiotics of cefixime, cefotaxime,
vancomycin, and tetracycline was demonstrated [49]. The
results proved that consumption of turmeric during the
treatment of Staph. aureus infections with these antibiotics
especially cefixime can be possibly helpful. Curcumin also
demonstrated a synergistic effect in combination with some
antibiotics, including ampicillin, oxacillin, and norfloxacin
against methicillin-resistant Staph. aureus strain (MRSA)
[20]. The synergistic effect of curcumin with ciprofloxacin
against MRSA has also been reported, although there is an
evidence of its antagonistic activity against S. typhi and S.
typhimurium in combination with ciprofloxacin [49, 50].
Strongly bound metal complexes to antimicrobial agents
are introduced as another possible way for synergistic activity
of respective antimicrobial agents through elevation of the
binding effect of them to the bacterial walls. Complexes
of curcumin with cobalt nanoparticles showed increased
antibacterial activity against E. coli [51]. Additionally, fab-
rication of silver nanocomposite films impregnated with
curcumin showed the stronger antibacterial activity against
E. coli. It was shown that the bactericidal activity of sodium
carboxymethyl cellulose silver nanocomposite films (SCMC
SNCFs) as an effective antibacterial material was improved
by loading of curcumin with SCMC SNCFs [52]. In another
in situ investigation, the synergistic effect of curcumin encap-
sulated chitosan-[poly (vinyl alcohol)] silver nanocomposite
films was shown. The novel antimicrobial films with pro-
nounced antimicrobial exhibition against E. coli proved to
be potential antibacterial material for treating infections or
wound dressing [53].
2.2. Anti-Biofilm Activity. Secretion of exopolysaccharide
alginate via different stimulators such as aminoglycosides
and imipenem consumption caused the increase in biofilm
volume of P. aeruginosa. Anti-biofilm activity of curcumin
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against two strains of P. aeruginosa isolated from deep oro-
pharyngeal swap samples of two cystic fibrosis patients with
MIC values of 16 𝜇g/mL was investigated by crystal violet
staining method. The curcumin treatment of the strains with
MIC concentrations did not reveal noteworthy elevation in
biofilm optical density [54]. In addition, in another study
curcumin showed the potential for reduction of biofilm initi-
ation genes, inhibition of 31 quorum sensing (QS) genes, and
downregulation of virulence factors including acyl homoser-
ine lactone (HSL) production, elastase/protease activity, and
pyocyanin biosynthesis. The antimicrobial activities led to
reduction of pathogenicity in Arabidopsis thaliana and
Caenorhabditis elegans as whole plant and animal infected
models with P. aeruginosa [7]. The results exhibited that
curcumin can be a potential candidate for P. aeruginosa infec-
tions in special infections characterized by biofilm formation,
although further comprehensive studies are needed for the
approval.
In some cases the adverse effects of curcumin against
different antibiotics were shown. Ciprofloxacin is the most
effective antibiotic against typhoidal and nontyphoidal infec-
tion of Salmonella. The main mechanism for antibacterial
activity of ciprofloxacin is through SOS response, induction
of chromosome fragmentation, and the production of ROS
in the bacterial cell. The in vivo and in vitro investigations on
curcumin together with ciprofloxacin showed that, through
interference with ciprofloxacin activity, it caused an elevation
in proliferation of Salmonella typhi and Salmonella enterica
serovar Typhimurium (S. typhimurium). Although curcumin
could not suppress the ciprofloxacin-induced gyrase inhibi-
tion, it protected Salmonella against oxidative burst induced
by interferon 𝛾 (IFN𝛾) or ciprofloxacin via owing strong ant-
ioxidant effect. The results demonstrated the curcumin by
suppressing the antibacterial effect of IFN𝛾 or ciprofloxacin
might increase the Salmonella pathogenesis [55].The study of
curcumin activity in a murine model of typhoid fever exhib-
ited an elevation of Salmonella typhimurium pathogenicity
and increased resistance to antimicrobial agents including
antimicrobial peptides, nitrogen species, and reactive oxygen.
Upregulation of genes involved in antioxidative function like
mntH, sitA, and sodA as well as other genes involved in
resistance to antimicrobial peptides including pmrD and
pmrHFIJKLM was considered as a possible cause for the
mentioned elevated tolerance. Curcumin also induced upre-
gulation effect on SPI2 genes involved in intracellular survival
and downregulation activity on SPI1 genes involved for entry
within epithelial cells. This information proved that the
indiscriminate use of curcumin should probably inhibit the
pathogenesis of Salmonella [55]. Additionally, curcumin also
at a dose 500𝜇g/disc showed antagonistic activity on the
bactericidal effect of nalidixic acid against clinical strain of
Staph. aureus investigated by disc diffusion method [49].
3. Antiviral Activity
Lack of effective therapeutics for the most of viral diseases,
emergence of antiviral drug resistance, and high cost of some
antiviral therapies necessitate finding new effective antivi-
ral compounds [56, 57]. Additionally, the existing antiviral
therapies are not always well-tolerated or quite effective
and satisfactory [58]. Hence, the increasing requirement for
antiviral substances will be more highlighted. Plants as a rich
source of phytochemicals with different biological activities
including antiviral activities are in interest of scientists [59,
60]. It has been demonstrated that curcumin as a plant deri-
vative has a wide range of antiviral activity against different
viruses. Inosine monophosphate dehydrogenase (IMPDH)
enzyme due to rate-limiting activity in the de novo synthesis
of guanine nucleotides is suggested as a therapeutic target for
antiviral and anticancer compounds. Among the 15 different
polyphenols, curcumin through inhibitory activity against
IMPDH effect in either noncompetitive or competitive man-
ner is suggested as a potent antiviral compound via this
process [61]. The study of different bioconjugates of cur-
cumin, namely, di-O-tryptophanylphenylalanine curcumin,
di-O-decanoyl curcumin, di-O-pamitoyl curcumin, di-O-
bis-(𝛾,𝛾)folyl curcumin, C4-ethyl-O-𝛾-folyl curcumin, and
4-O-ethyl-O-𝛾-folyl curcumin, against variety of viruses
including parainfluenza virus type 3 (PIV-3), feline infectious
peritonitis virus (FIPV), vesicular stomatitis virus (VSV),
herpes simplex virus (HSV), flock house virus (FHV), and
respiratory syncytial virus (RSV) assessed by MTT test
showed the potent antiviral activity of curcumin and its
bioconjugates against different viral pathogens for further
studies. Also, di-O tryptophanylphenylalanine curcumin and
di-O-decanoyl curcumin revealed remarkable antiviral activ-
ity against VSV and FIPV/FHV with EC
50
values of 0.011𝜇M
and 0.029 𝜇M, respectively. However, bioconjugates did not
exhibit significant antiviral activity against IIIB and ROD
strains of type 1 human immunodeficiency virus (HIV-1) in
MT-4 cells [62]. Table 1 summarizes the antiviral activity of
C. longa and curcumin and possible mechanisms underlying
inhibitory effects.
Viral long terminal repeat (LTR) has a critical role in
transcription of type 1 human immunodeficiency virus (HIV-
1) provirus. Inhibition of LTR activity can be a possible
pathway for antiviral drug candidates in order to block HIV-
1 replication [63, 64]. Curcumin proved to be an effective
compound to inhibit theHIV-1 LTR-directed gene expression
without anymajor effects on cell viability [24]. Curcumin and
its derivatives, namely, reduced curcumin, allyl-curcumin,
and tocopheryl-curcumin, revealed 70% to 85% inhibition
in Tat protein transactivation of HIV-1 LTR measured by
𝛽-galactosidase activities of HeLa cells which in HIV-1 LTR
was fused to the indictor of lacZ gene. Tocopheryl-curcumin
demonstrated the most inhibition activity with 70% inhi-
bition at 1 nM compared to 35% inhibition of curcumin at
this concentration [25]. In addition, curcumin inhibited the
acetylation of Tat protein of HIV significantly by p300 asso-
ciated with suppression of HIV-1 multiplication. Curcumin
by targeting the acetyltransferase proteins of p300/CREB-
binding protein (CBP) can be a potent compound for com-
binatorial HIV therapeutics [28]. Curcumin was found to be
an inhibitor ofHIV-1 andHIV-2 protease with IC
50
of 100 𝜇M
and 250 𝜇M, respectively. The curcumin boron complexes
exhibited noteworthy inhibition reduced to the IC
50
value of
6 𝜇M with time-dependent activity. The elevated affinity of
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Table 1: Antiviral activities of Curcuma longa L. and curcumin.
Virus Antiviral substances Description of antiviral activity type Reference
HIV
Curcumin Inhibition of HIV-1 LTR-directed gene expression [24]
Curcumin, reduced curcumin, allyl-curcumin,
tocopheryl-curcumin
Inhibition of Tat-mediated transactivation of HIV-1
LTR [25]
Curcumin, curcumin boron complexes Inhibition of HIV-1 and HIV-2 proteases [26]
Curcumin Inhibition of HIV-1 Integrase [27]
Curcumin Inhibition of Tat protein acetylation [28]
Curcumin No antiviral effect in clinical trial [29]
Influenza Curcumin Inhibition of haemagglutination [30]
HSV-1 Curcumin, gallium-curcumin, Cu-curcumin Reduction of HSV-1 replication [31, 32]
HSV-2 Curcumin Significant protection in mouse model [33]
Coxsackievirus Curcumin Replication inhibition through UPS dysregulation [34]
HBV Aqueous extract Suppression of HBV replication by increasing the p53level [35]
HCV Curcumin Decrease of HCV replication by suppressing theAkt-SREBP-1 pathway [36]
HPV Curcumin Inhibition expression of viral oncoproteins of E6 and E7 [37]
HPV Curcumin Downregulation effect on the transcription of HPV-18 [38]
JEV Curcumin Reduction in production of infective viral particles [39]
HTLV-1 Curcumin Downregulation of JunD protein in HTLV-1-infectedT-cell lines [40]
boron derivatives of curcumin is possibly associated with the
attachment of the orthogonal domains of the compound in
intersecting sites within the substrate-binding cavity of the
protease [26]. Integrase as another essential enzyme forHIV-1
replication was found to be inhibited by curcumin with IC
50
value of 40 𝜇M. Inhibition of deletion mutant of integrase
containing only amino acids 50–212 indicated that curcumin
possibly interacts with catalytic core of the enzyme.The study
of energy minimization and the structural analogs of cur-
cumin elicited that an intramolecular stacking of two phenyl
rings of curcumin is possibly responsible for anti-integrase
activity via bringing the hydroxyl groups into close proximity
[27]. However, rosmarinic acid and dicaffeoyl methane as
two curcumin analogs showed noteworthy inhibitory activity
against integrase of HIV-1 with IC
50
values less than 10 𝜇M
with the slow rate of binding to the enzyme assessed by kinetic
studies [65]. However, through a clinical trial investigation
on curcumin as an anti-HIV compound in 40 patients in
eight weeks it was shown that there is no reduction in viral
load or elevation in CD4 counts. But patients claimed that
they preferred to take the curcumin in order to tolerate the
minor gastrointestinal sufferings and feel better [29]. This
demonstrated that clinical trials can possibly show up with
the results completely different from in vitro studies. The
clinical trial of clear liquid soap containing 0.5%w/v ethanol
extract of C. longa rhizome on HIV patients reduced the
wound infections and 100% decrease in itching symptom and
it also affected the abscess to convert to dryness scabs (78.6%)
within 2 weeks [16].
Curcumin showed the anti-influenza activity against
influenza viruses PR8, H1N1, and H6N1. The results showed
more than 90% reduction in virus yield in cell culture using
30 𝜇M of curcumin. The plaque reduction test elicited the
approximate EC
50
of 0.47 𝜇M for curcumin against influenza
viruses [30]. In H1N1 and also H6N1 subtypes, the inhibition
of haemagglutinin interaction reflected the direct effect of
curcumin on infectivity of viral particles and this has proved
by time of drug addiction experiment. Additionally, unlike
amantadine, viruses developed no resistance to curcumin.
The methoxyl derivatives of curcumin also did not show
noteworthy role in the haemagglutination [30]. These results
proved the significant potential of curcumin for inhibition of
influenza.
In vitro study of curcumin and its derivatives, namely,
gallium-curcumin and Cu-curcumin, exhibited remark-
able antiviral activity against herpes simplex virus type 1
(HSV-1) in cell culture with IC
50
values of 33.0microg/mL,
13.9microg/mL, and 23.1microg/mL, respectively. The 50%
cytotoxic concentration (CC
50
) of the respective compounds
on Vero cell line showed to be 484.2𝜇g/mL, 255.8 𝜇g/mL,
and 326.6 𝜇g/mL, respectively [31]. Curcumin considerably
decreased the immediate early (IE) gene expression and
infectivity of HSV-1 in cell culture assays. Curcumin has
an effect on recruitment of RNA polymerase II to IE gene
promoters through mediation of viral transactivator protein
VP16, by an independent process of p300/CBP histone acetyl
transferase effect [32]. In vitro replication of HSV-2 could
be decreased by curcumin with ED
50
value of 0.32mg/mL
[32]. Moreover, an in vivo study on mouse model with
intravaginal HSV-2 challenge showed significant protection
against HSV-2 infection due to administration of curcumin.
This study showed that curcumin can be a good candidate
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for developing the antiviral products used intravaginally by
women for protection against sexually transmitted herpes
virus infection [33]. Indeed, a metallo-herbal complex of
curcumin with copper (Cu2+) demonstrated microbicidal
effect for further studies of vaginal gel with antiviral activity
[66].
Coxsackieviruses cause a variety of diseases such as
dilated cardiomyopathy and myocarditis. Coxsackievirus B3
(CVB3) in spite of extensive investigations is still a major
human pathogen without specific effective and approved
treatment [67, 68]. Curcumin exhibited the antiviral activity
against coxsackievirus by reduction of viral RNA expres-
sion, protein synthesis, and virus titer. In addition, it was
found to have a protective effect on cells against virus-
induced apoptosis and cytopathic activity. Analysis of dif-
ferent pathways showed that curcumin forced its potent
antiviral effect in inhibition of coxsackievirus replication
through dysregulation of the ubiquitin-proteasome system
(UPS) [34].The recent studies proved that the UPS-mediated
protein modification or degradation is an essential factor in
the regulation of coxsackievirus replication [69].
Liver diseases associated with viral infections are major
pandemics [70].The fact that hepatitis B virus (HBV) elevates
the possibility for the hepatocellular carcinoma (HCC) devel-
opment some 100-fold and 695.900 deaths occurred due to
liver cirrhosis and HCC worldwide in 2008 makes the need
to find new antivirals against hepatitis viruses [71, 72]. The
study of antiviral effect of aqueous extract of Curcuma longa
rhizoma against HBV in HepG 2.2.15 cells containing HBV
genomes showed repression of HBsAg secretion from liver
cells without any cytotoxic effect. It also suppressed the HBV
particles production and the rate of mRNA production of
HBV on infected cells.TheCurcuma longa extract suppressed
HBV replication by increasing the rate of p53 protein through
enhancing the stability of the protein aswell as transactivating
the transcription of p53 gene. It was understood that the
extract has suppressed HBV enhancer I and X promoter
leading to repression of HBx gene transcription by affecting
p53 [35]. In vitro investigation of the antiviral activity of
curcumin Huh7 replicon cells expressing the hepatitis C
virus (HCV) indicated that curcumin can be a potent anti-
HCV compound. Results showed the decrease in HCV gene
expression and replication through suppressing the Akt-
SREBP-1 pathway. In addition, the mixture of curcumin and
IFN𝛼 as the known anti-HCV therapy induced profound
inhibitory activity onHCVreplication anddemonstrated that
curcumin can be possibly used as a complementary therapy
for HCV [36].
High-risk human papillomaviruses (HPVs) infection via
the expression of E6 and E7 viral oncoproteins has a crit-
ical role for development of cervical carcinoma. Curcumin
showed the inhibitory activity against the expression of E6
and E7 genes of HPV-16 and HPV-18 as two main highly
oncogenic human papilloma viruses [37]. The transcription
factor AP-1 is a critical factor for transcriptional regulation
of high-risk HPVs such as HPV-16 and HPV-18. Curcumin
downregulates the AP-1 binding activity in HeLa cells with
decreasing effect on the transcription of HPV-18 [38]. The
results showed that curcumin through apoptosis modulation
and also prevention of NF𝜅B and AP-1 translocation associ-
ated with downregulation of viral oncogenes and decreasing
the transcription of HPVs can be a good candidate for the
management of highly oncogenic HPV infections [37, 38].
Japanese encephalitis virus (JEV) as an important ende-
mic arbovirus in Southeast Asia is a major cause of acute
encephalopathywhich generally affects the children and leads
to death in one third of patients.The permanent neuropsychi-
atric sequel is a complication for many survivors from JEV
due to ineffective therapeutic measure [73].The investigation
of antiviral activity of curcumin on Neuro2a cell line infected
with JEV showed reduction in production of infectious
viral particles through inhibition of ubiquitin-proteasome
system. The results of in vitro study indicated that curcumin
through modulating cellular levels of stress-related proteins,
reducing proapoptotic signaling molecules, restoration of
cellularmembrane integrity, and reduction in reactive oxygen
species in cellular level imparts neuroprotection and can be a
potential for further investigations [39].
Oncogenesis by human T-cell leukemia virus type 1 as
an etiologic factor of adult T-cell leukemia (ATL) is critically
dependent on the activation of the activator protein 1 (AP-
1) [74]. The DNA binding and transcriptional effect of AP-1
in HTLV-1-infected T-cell lines were suppressed by curcumin
treatment. Curcumin also inhibited the expression of JunD
protein as an important factor in AP-1-DNA complex in
HTLV-1-infected T-cells as well as HTLV-1 Tax-induced AP-
1 transcriptional effect. Cell cycle arrest and inducing of
apoptosis were found to be possible mechanisms against
HTLV-1 replication in infected T-cell line by curcumin.
Suppression of AP-1 activity possibly through decreasing
the expression of JunD protein is introduced as a possible
pathway for anti-ATL activity of curcumin [40].
4. Antifungal Activity
Substances and extracts isolated from different natural
resources especially plants have always been a rich arse-
nal for controlling the fungal infections and spoilage. Due
to extensive traditional use of turmeric in food products,
various researches have been done in order to study the
turmeric and curcumin with the aspect of controlling fungal
related spoilage and fungal pathogens. The study of addition
the turmeric powder in plant tissue culture showed that
turmeric at the 0.8 and 1.0 g/L had appreciable inhibitory
activity against fungal contaminations [75]. The methanol
extract of turmeric demonstrated antifungal activity against
Cryptococcus neoformans and Candida albicans with MIC
values of 128 and 256𝜇g/mL, respectively [16]. The study
of hexane extract of C. longa at 1000mg/L demonstrated
antifungal effect against Rhizoctonia solani, Phytophthora
infestans, and Erysiphe graminis. It was also shown that
1000mg/L of ethyl acetate extract of C. longa exhibitedin-
hibitory effect against R. solani, P. infestans, Puccinia recon-
dita, and Botrytis cinerea.Curcumin at 500mg/L also showed
antifungal activity against R. solani, Pu. recondita, and P.
infestans [76]. Curcumin and turmeric oil exert antifungal
effect against two phytophagous fungi, namely, Fusarium
solani and Helminthosporium oryzae. Turmeric oil exhibited
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the most effective antifungal activity against F. solani and
H. oryzae with IC
50
of 19.73 and 12.7 𝜇g/mL, respectively
[77]. The crude methanol extract of C. longa has inhibitory
effect against some clinical isolates of dermatophytes. It was
demonstrated that 18-month-old and freshly distilled oil
isolated from rhizome of C. longa showed the most potent
antifungal effect against 29 clinical isolates of dermatophytes
with MIC values of 7.2 and 7.8mg/mL, respectively [78].
Trichophyton rubrum, T. mentagrophytes, Epidermophyton
floccosum, and Microsporum gypseum were suppressed by
1 : 40–1 : 320 dilutions of turmeric oil. An in vivo study
on infected guinea pigs with T. rubrum demonstrated that
dermal application of turmeric oil (dilution 1 : 80) induced an
improvement in healing of the lesions after 2–5 days and it
caused the lesions after 6-7 days of consumption to vanish.
Turmeric oil also showed activity against pathogenic molds
such as Sporothrix schenckii, Exophiala jeanselmei, Fonsecaea
pedrosoi, and Scedosporium apiospermum with MIC values
of 114.9, 459.6, 459.6, and 114.9 𝜇g/mL, respectively [79].
However, curcumin showed more significant effect against
Paracoccidioides brasiliensis than fluconazole, although it
did not affect the growth of Aspergillus species [80]. The
possible mechanism underlying the mentioned antifungal
effect was found to be downregulation of Δ5,6 desaturase
(ERG3) leading to significant reduction in ergosterol of
fungal cell. Reduction in production of ergosterol results in
accumulations of biosynthetic precursors of ergosterol which
leads to cell death via generation of ROS [81]. Reduction in
proteinase secretion and alteration of membrane-associated
properties ofATPase activity are other possible critical factors
for antifungal activity of curcumin [82].
Resistant strain development among the Candida species
against existing antifungal drugs became a critical problem
for therapeutic strategies.Thereby, finding new anti-Candida
substances seems to be crucial [83]. The study of curcumin
against 14 strains of Candida including 4 ATCC strains and
10 clinical isolates showed that curcumin is a potent fungicide
compound against Candida species with MIC values range
from 250 to 2000𝜇g/mL [82]. In another study, anti-Candida
activity of curcumin was demonstrated against 38 different
strains of Candida including some fluconazole resistant
strains and clinical isolates of C. albicans, C. glabrata, C.
krusei, C. tropicalis, and C. guilliermondii. The MIC
90
values
for sensitive and resistant strains were 250–650 and 250–
500𝜇g/mL, respectively. Intracellular acidification via inhi-
bition of H+-extrusion was identified as possible mechanism
for cell death of Candida species [84]. The development of
hyphae was proved to be inhibited by curcumin through tar-
geting the global suppressor thymidine uptake 1 (TUP1) [81,
85]. Curcumin also showed inhibitory effect on Cryptococcus
neoformans and C. dubliniensis with MIC value of 32mg/L
[80]. One of themajor complications during therapies against
chronic asthma is oropharyngeal candidiasis. Curcumin as
a potential candidate for the treatment of candidosis with
anti-inflammatory activity was studied in a murine model
of asthma. Oral administrator of Curcumin is more effective
than dexamethasone in reducing fungal burden in BALB/c
mice. It also significantly decreased pathological changes
in asthma [86]. Adhesion of Candida species isolated from
AIDS patients to buccal epithelial cells is also markedly
inhibited by curcumin and it was found to be more effective
compared to fluconazole [80].
The investigation of curcumin mediation for photody-
namic therapy can reduce the biofilm biomass of C. albicans,
C. glabrata, and C. tropicalis. The results demonstrated that
association of four LED fluences for light excitation with
40 𝜇M concentration of curcumin at 18 J/cm2 inhibited up to
85%metabolic activity of the tested Candida species. The use
of curcumin with light proved to be an effective method for
noteworthy improvement in the antifungal activity against
planktonic form of the yeasts [87]. Photodynamic effect con-
siderably decreased C. albicans viability in either planktonic
or biofilm cultures probably through increasing the uptake of
curcumin by cells. However, to a lesser extent, photodynamic
therapy was found to be phototoxic to the macrophages.
[88]. A study on a murine model of oral candidiasis was
done for gathering reliable data for curcumin-mediated
photodynamic therapy efficacy in vivo. Results proved that
all exposures to curcumin with LED light markedly inhibited
the C. albicans viability after photodynamic therapy without
harming the host tissue of mice. However, 80𝜇M of cur-
cumin in association with light showed the best decrease in
colony counts of C. albicans [89]. These results showed that
curcumin is a high potential photosensitizer compound for
fungicidal photodynamic therapy especially against Candida
species.
The strong antifungal activity of C. longa rhizome and its
low side effect were the main reasons to investigate its proba-
ble synergistic effect with existing fungicides. The synergistic
activity of curcumin with five azole and two polyene drugs
including voriconazole, itraconazole, ketoconazole, micona-
zole, fluconazole, amphotericin B, and nystatin showed 10–
35-fold reduction in the MIC values of the fungicides against
21 clinical isolates of C. albicans. The synergistic activity of
curcumin with amphotericin B and fluconazole could be
associated with the accumulation of ROS which will be sup-
pressed by adding an antioxidant [85].The study of 200 clini-
cal isolates of Candida species includingC. tropicalis, C. kefyr,
C. krusei, C. guilliermondii, C. glabrata, C. parapsilosis, and
C. albicans demonstrated fungicidal activity for curcumin
with MIC value of 32–128𝜇g/mL. Combination of curcumin
with amphotericinB also exhibited synergistic activity against
tested Candida species, although fluconazole and curcumin
in some cases showed additive effects rather than synergistic
activity. These results proved that combination of curcumin
with existing fungicidal agents can provide more significant
effect against systemic fungal infections like candidemia and
candidosis [90]. In silico analysis demonstrated that cur-
cumin by attaching to albumin serum in a separate binding
site of amphotericin B and forming the complex alleviated
the adverse side effect of amphotericin B via delaying the
red cell lysis. The stability and aqueous solubility of the
complex of curcumin and amphotericin B with albumin
serum can be a potential candidate for the treatment of
visceral leishmaniasis and systemic fungal infections [91].The
in vivo study of combination of curcumin and piperine in
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murine model of Candida infection also revealed synergistic
effect with noteworthy fungal load reduction in kidney of
Swiss mice [85]. The mixture of curcumin and ascorbic acid
against different strains ofCandida also exhibited 5- to 10-fold
reduction ofMIC values compared to the time that curcumin
was tested alone [92]. These synergistic effects showed that
curcumin in combination with different fungicide materials
can significantly elicit synergistic activity to enhance the
efficacy of existing antifungal strategies.
5. Enhancing the Bioavailability
and Solubility of Curcumin to
Improve Antimicrobial Activities
The optimum potential of curcumin is limited because of
poor oral bioavailability and insufficient solubility in aqueous
solvents leading to poor absorption, fast metabolism, and
quick systemic elimination [5, 93]. For overcoming this obsta-
cle, nanocarriers like curcumin-loaded PLGA (poly lactide-
co-glycolide) and curcumin nanoparticle formulation were
investigated and their better bioactivity and bioavailability
as well as increased cellular uptake compared to curcumin
were reported [5]. Another study revealed that heat-extracted
curcumin elevated the solubility of curcumin 12-fold without
significant disintegration due to heat treatment.Modification
of 4-hydroxy-2-nonenal (HNE) as a critical oxidation by-
product involved in disease pathogenesis via cytotoxicity,
genotoxicity, and mutagenicity is inhibited 80% by heat-
solubilized curcumin and suggested a possiblemechanism for
inducing bioactivity of curcumin [94].The study of nanocur-
cumin as a nanoparticle of curcuminwith the size of 2–40 nm
processed by awet-milling technique, showed curcumin to be
more freely dispersible in water leading to more significant
antimicrobial activity against Staph. aureus, E. coli, P. aerugi-
nosa, B. subtilis, and two fungi of P. notatum and A. niger due
to reduced particle size and enhanced bioavailability [95, 96].
However, nanocurcumin demonstrated more noteworthy
activity against Gram-positive bacteria rather than Gram-
negatives [95]. In another study to improve the stability
and solubility of curcumin, microencapsulation process was
investigated. Microcapsule of curcumin with improved sol-
ubility is suitable as a preservative and colorant in food
industry and it exhibited potent antimicrobial effect against
food-borne pathogens including E. coli, Staph. aureus, B.
subtilis, B. cereus, Yersinia enterocolitica, Penicillium notatum,
and Saccharomyces cerevisiae with MIC values ranging from
15.7 to 250 𝜇g/mL. It was demonstrated that Gram-positive
bacteria were more susceptible to the microcapsulated cur-
cumin compared to Gram-negatives. However, antifungal
effect was found to be stronger than the bactericidal effect
[97, 98].
6. Conclusion
All previous investigations have shown the extensive antimi-
crobial activity of curcumin, although in vivo studies in
some cases reported the less effective results of curcumin
inhibitory effect. Among all former studies on antibacterial
activity of curcumin the most promising result is against
Helicobacter pylori, at least for using the curcumin as a
complementary compound in combination with other exist-
ing medicines to decrease the symptoms of gastritis. The
extensive antiviral effects of curcumin against different viral
pathogens nominate this compound as an antiviral drug
candidate to develop new antivirals from natural resources
against sensitive viruses especially by developing different
curcumin derivatives. However, using curcumin or its deriva-
tives as antiviral compounds needs further investigations.
Regarding the studies on antifungal activities of curcumin
the most significant effect was found against Candida species
and Paracoccidioides brasiliensis, although curcumin revealed
fungicide effect against various fungi. In spite of various
biological activities of curcumin, no real clinical uses have
been reported for this compound and still clinical trials are
undergoing for different ailments and diseases, namely, colon
and pancreatic cancers, multiple myeloma, myelodysplastic
syndromes, Alzheimer, and psoriasis [99]. Until 2013, more
than 65 clinical trials on curcumin have been carried out, and
still more is underway. This polyphenol compound is now
used as a supplement in several countries, namely, China,
India, Japan, Korea, SouthAfrica, theUnited States,Thailand,
and Turkey [100].
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